NASDAQ : AQST
Aquestive Therapeutics, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 3.89 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 488.24M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 473.18M |
| Enterprise Value | 433.72M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 125.51M |
| Shares Outstanding | 125.51M |
| Shares Change (YoY) | +27.37% |
| Shares Change (QoQ) | +1.94% |
| Owned by Insiders (%) | 4.03% |
| Owned by Institutions (%) | 50.70% |
| Float | 113.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.75 |
| Forward PS | 9.91 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 8.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.19 |
| Quick Ratio | 6.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.23 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -29.20% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -45.62% |
| Weighted Average Cost of Capital (WACC) | 13.46% |
| Revenue Per Employee | $367,939 |
| Profits Per Employee | -$532,156 |
| Employee Count | 147 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 2.30 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -44.72% |
| 50-Day Moving Average | 4.64 |
| 200-Day Moving Average | 4.21 |
| Relative Strength Index (RSI) | 34.94 |
| Average Volume (20 Days) | 2,162,296 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 27.60M |
| Short Previous Month | 28.75M |
| Short % of Shares Out | 21.99% |
| Short % of Float | 24.42% |
| Short Ratio (days to cover) | 13.15 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 54.09M |
| Gross Profit | 36.26M |
| Operating Income | -52.75M |
| Pretax Income | -78.23M |
| Net Income | -78.23M |
| EBITDA | -52.20M |
| EBIT | -52.75M |
| Loss Per Share | -$0.65 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 98.49M |
| Total Debt | 59.03M |
| Net Cash | 39.46M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | -56.59M |
| Book Value Per Share | -0.45 |
| Working Capital | 102.02M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -45.37M |
| Capital Expenditures | -584,000 |
| Depreciation & Amortization | 544,000 |
| Net Borrowing | 9.31M |
| Free Cash Flow | -45.95M |
| FCF Per Share | -$0.37 |
Margins
| Measure | Value |
|---|
| Gross Margin | 67.04% |
| Operating Margin | -97.52% |
| Pretax Margin | -144.63% |
| Profit Margin | -144.63% |
| EBITDA Margin | -96.51% |
| EBIT Margin | -97.52% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -27.37% |
| Shareholder Yield | -27.37% |
| Earnings Yield | -17.27% |
| FCF Yield | -9.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.33 |
| Price Target Difference | 147.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 33.81% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.25 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |